Download PDF
Facial Plast Surg 2020; 36(02): 133-140
DOI: 10.1055/s-0040-1709142
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Mohs Surgery versus Standard Local Excision for Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma Skin Cancer

Timothy M. Johnson
1   Department of Dermatology, Otolaryngology, and Surgery, University of Michigan, Ann Arbor, Michigan
,
Noah R. Smith
2   Department of Dermatology, University of Michigan, Ann Arbor, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
15 May 2020 (online)

    Permissions and Reprints

Corrected by:

Erratum: Mohs Surgery versus Standard Local Excision for Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma Skin CancerFacial Plast Surg 2020; 36(02): e1-e1
DOI: 10.1055/s-0040-1721103

Abstract

Basal cell carcinoma, squamous cell carcinoma, and melanoma represent the three most common skin cancers that occur on the face. The most common surgical treatments for facial skin cancers are Mohs surgery and standard local excision. The effective utilization of either of these techniques is based on tumor and patient risk stratification incorporating known risk factors for occult invasion and local recurrence, combined with patient comorbidities, expectations, and desires. Best available evidence highlights multiple and consistent risk factors for each specific skin cancer type, and dictate local control rates reported in the literature. Recognizing gaps in the literature, we compare and review surgical treatment guidelines and data for standard local excision versus Mohs surgery for cutaneous nonmelanoma and melanoma skin cancer. This article serves as a resource for optimal therapeutic decision making for surgical management of skin cancer on the face.

Keywords

basal cell carcinoma - squamous cell carcinoma - melanoma - Mohs surgery - standard local excision
 

  • References

  • 1 American Cancer Society. Cancer facts and figures 2019 . Available at: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html . Accessed January 14, 2019
    PubMed
  • 2 Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch Dermatol 2010; 146 (03) 279-282
    CrossrefPubMedGoogle Scholar
  • 3 Chahal HS, Rieger KE, Sarin KY. Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age. J Am Acad Dermatol 2017; 76 (02) 353-354
    CrossrefPubMedGoogle Scholar
  • 4 American Cancer Society. What are basal and squamous cell skin cancers? Available at: http://www.cancer.org/cancer/skincancer-basalandsquamouscell/detailedguide/skin-cancer-basal-and-squamous-cell-what-is-basal-and-squamous-cell . Accessed January 31, 2018
    PubMed
  • 5 Guy Jr. GP, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011. Am J Prev Med 2015; 48 (02) 183-187
    CrossrefPubMedGoogle Scholar
  • 6 Vaidya TS, Mori S, Dusza SW, Rossi AM, Nehal KS, Lee EH. Appearance-related psychosocial distress following facial skin cancer surgery using the FACE-Q skin cancer. Arch Dermatol Res 2019; 311 (09) 691-696
    CrossrefPubMedGoogle Scholar
  • 7 Skin Cancer Foundation. Skin cancer facts and statistics. Available at: https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/ . Accessed December 1, 2019
    PubMed
  • 8 National Comprehensive Cancer Network. NCCN guidelines and clinical resources. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf . Accessed December 20, 2019
    PubMed
  • 9 National Comprehensive Cancer Network. NCCN Guidelines: Squamous Cell Skin Cancer. Available at: https://www.nccn.org/patients/guidelines/content/PDF/squamous_cell-patient.pdf . Accessed December 20, 2019
    PubMed
  • 10 Orengo IF, Salasche SJ, Fewkes J, Khan J, Thornby J, Rubin F. Correlation of histologic subtypes of primary basal cell carcinoma and number of Mohs stages required to achieve a tumor-free plane. J Am Acad Dermatol 1997; 37 (3, Pt 1): 395-397
    CrossrefPubMedGoogle Scholar
  • 11 Leffell DJ, Headington JT, Wong DS, Swanson NA. Aggressive-growth basal cell carcinoma in young adults. Arch Dermatol 1991; 127 (11) 1663-1667
    CrossrefPubMedGoogle Scholar
  • 12 Salasche SJ, Amonette RA. Morpheaform basal-cell epitheliomas. A study of subclinical extensions in a series of 51 cases. J Dermatol Surg Oncol 1981; 7 (05) 387-394
    CrossrefPubMedGoogle Scholar
  • 13 Batra RS, Kelley LC. Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery. Arch Dermatol 2002; 138 (08) 1043-1051
    CrossrefPubMedGoogle Scholar
  • 14 Haws AL, Rojano R, Tahan SR, Phung TL. Accuracy of biopsy sampling for subtyping basal cell carcinoma. J Am Acad Dermatol 2012; 66 (01) 106-111
    CrossrefPubMedGoogle Scholar
  • 15 Johnson TM, Tromovitch TA, Swanson NA. Combined curettage and excision: a treatment method for primary basal cell carcinoma. J Am Acad Dermatol 1991; 24 (04) 613-617
    CrossrefPubMedGoogle Scholar
  • 16 Welsch MJ, Troiani BM, Hale L, DelTondo J, Helm KF, Clarke LE. Basal cell carcinoma characteristics as predictors of depth of invasion. J Am Acad Dermatol 2012; 67 (01) 47-53
    CrossrefPubMedGoogle Scholar
  • 17 Ratner D, Lowe L, Johnson TM, Fader DJ. Perineural spread of basal cell carcinomas treated with Mohs micrographic surgery. Cancer 2000; 88 (07) 1605-1613
    CrossrefPubMedGoogle Scholar
  • 18 Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia III. Perineural invasion. J Am Acad Dermatol 2005; 53 (03) 458-463
    CrossrefPubMedGoogle Scholar
  • 19 Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol 2005; 53 (03) 452-457
    CrossrefPubMedGoogle Scholar
  • 20 Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005; 53 (03) 445-451
    CrossrefPubMedGoogle Scholar
  • 21 van Loo E, Mosterd K, Krekels GA. , et al. Surgical excision versus Mohs micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer 2014; 50 (17) 3011-3020
    CrossrefPubMedGoogle Scholar
  • 22 Ron E, Modan B, Preston D, Alfandary E, Stovall M, Boice Jr JD. Radiation-induced skin carcinomas of the head and neck. Radiat Res 1991; 125 (03) 318-325
    CrossrefPubMedGoogle Scholar
  • 23 Canueto J, Burguillo J, Moyano-Bueno D. , et al. Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practice. J Am Acad Dermatol 2019; 80 (01) 106-113e2
    CrossrefPubMedGoogle Scholar
  • 24 Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia II. Perineural invasion. J Am Acad Dermatol 2005; 53 (02) 261-266
    CrossrefPubMedGoogle Scholar
  • 25 Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol 1992; 26 (3, Pt 2): 467-484
    CrossrefPubMedGoogle Scholar
  • 26 Cañueto J, Martín-Vallejo J, Cardeñoso-Álvarez E, Fernández-López E, Pérez-Losada J, Román-Curto C. Rapid growth rate is associated with poor prognosis in cutaneous squamous cell carcinoma. Clin Exp Dermatol 2018; 43 (08) 876-882
    CrossrefPubMedGoogle Scholar
  • 27 Moyer JS, Rudy S, Boonstra PS. , et al. Efficacy of staged excision with permanent section margin control for cutaneous head and neck melanoma. JAMA Dermatol 2017; 153 (03) 282-288
    CrossrefPubMedGoogle Scholar
  • 28 Tolkachjov SN, Brodland DG, Coldiron BM. , et al. Understanding Mohs micrographic surgery: a review and practical guide for the nondermatologist. Mayo Clin Proc 2017; 92 (08) 1261-1271
    CrossrefPubMedGoogle Scholar
  • 29 Gayre GS, Hybarger CP, Mannor G. , et al. Outcomes of excision of 1750 eyelid and periocular skin basal cell and squamous cell carcinomas by modified en face frozen section margin-controlled technique. Int Ophthalmol Clin 2009; 49 (04) 97-110
    CrossrefPubMedGoogle Scholar
  • 30 Kuijpers DI, Thissen MR, Berretty PJ, Ideler FH, Nelemans PJ, Neumann MH. Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg 2007; 33 (05) 579-587
    PubMedGoogle Scholar
  • 31 Rhodes LE, de Rie MA, Leifsdottir R. , et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143 (09) 1131-1136
    CrossrefPubMedGoogle Scholar
  • 32 Rowe DE, Carroll RJ, Day Jr CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15 (03) 315-328
    CrossrefPubMedGoogle Scholar
  • 33 Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135 (10) 1177-1183
    CrossrefPubMedGoogle Scholar
  • 34 Jaafar H. Intra-operative frozen section consultation: concepts, applications and limitations. Malays J Med Sci 2006; 13 (01) 4-12
    PubMedGoogle Scholar
  • 35 Mosterd K, Krekels GA, Nieman FH. , et al. Surgical excision versus Mohs micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol 2008; 9 (12) 1149-1156
    CrossrefPubMedGoogle Scholar
  • 36 Rowe DE, Carroll RJ, Day Jr CL. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989; 15 (04) 424-431
    CrossrefPubMedGoogle Scholar
  • 37 Rowe DE, Carroll RJ, Day Jr CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26 (06) 976-990
    CrossrefPubMedGoogle Scholar
  • 38 Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005; 53 (02) 253-260
    CrossrefPubMedGoogle Scholar
  • 39 National Comprehensive Cancer Network. NCCN guidelines: cutaneous melanoma. Available at: https://www.nccn.org/patients/guidelines/content/PDF/melanoma-patient.pdf . Accessed December 20, 2019
    PubMed
  • 40 Anderson KW, Baker SR, Lowe L, Su L, Johnson TM. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg 2001; 3 (03) 202-206
    CrossrefPubMedGoogle Scholar
  • 41 Beaulieu D, Fathi R, Srivastava D, Nijhawan RI. Current perspectives on Mohs micrographic surgery for melanoma. Clin Cosmet Investig Dermatol 2018; 11: 309-320
    CrossrefPubMedGoogle Scholar
  • 42 Miller CJ, Giordano CN, Higgins II HW. Mohs micrographic surgery for melanoma: as use increases, so does the need for best practices. JAMA Dermatol 2019
    PubMedGoogle Scholar
  • 43 Walling HW, Scupham RK, Bean AK, Ceilley RI. Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 2007; 57 (04) 659-664
    CrossrefPubMedGoogle Scholar
  • 44 Prieto VG, Argenyi ZB, Barnhill RL. , et al. Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions?. Am J Clin Pathol 2003; 120 (02) 203-208
    CrossrefPubMedGoogle Scholar